RU2016110874A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016110874A3 RU2016110874A3 RU2016110874A RU2016110874A RU2016110874A3 RU 2016110874 A3 RU2016110874 A3 RU 2016110874A3 RU 2016110874 A RU2016110874 A RU 2016110874A RU 2016110874 A RU2016110874 A RU 2016110874A RU 2016110874 A3 RU2016110874 A3 RU 2016110874A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361871275P | 2013-08-28 | 2013-08-28 | |
| US61/871,275 | 2013-08-28 | ||
| PCT/US2014/053244 WO2015031666A1 (en) | 2013-08-28 | 2014-08-28 | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016110874A RU2016110874A (ru) | 2017-10-04 |
| RU2016110874A3 true RU2016110874A3 (enExample) | 2018-06-27 |
Family
ID=51541330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016110874A RU2016110874A (ru) | 2013-08-28 | 2014-08-28 | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160361314A1 (enExample) |
| EP (1) | EP3038652B1 (enExample) |
| JP (1) | JP6479812B2 (enExample) |
| KR (1) | KR20160047521A (enExample) |
| CN (1) | CN106029099A (enExample) |
| AU (3) | AU2014312261A1 (enExample) |
| BR (1) | BR112016004358A8 (enExample) |
| CA (1) | CA2922684A1 (enExample) |
| ES (1) | ES2674361T3 (enExample) |
| MX (1) | MX2016002580A (enExample) |
| RU (1) | RU2016110874A (enExample) |
| WO (1) | WO2015031666A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016167511A2 (ko) * | 2015-04-14 | 2016-10-20 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| KR101772134B1 (ko) | 2015-04-14 | 2017-08-29 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| US11208630B2 (en) * | 2015-12-24 | 2021-12-28 | University Of Florida Research Foundation, Incorporated | AAV production using suspension adapted cells |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| SG11202005937QA (en) | 2018-01-08 | 2020-07-29 | G1 Therapeutics Inc | G1t38 superior dosage regimes |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP3947368B1 (en) * | 2019-04-04 | 2025-09-03 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| US20230019999A1 (en) | 2019-11-18 | 2023-01-19 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021176349A1 (en) * | 2020-03-05 | 2021-09-10 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
| WO2022063220A1 (en) * | 2020-09-25 | 2022-03-31 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical composition and use thereof for treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0722383A2 (pt) * | 2006-12-08 | 2012-06-05 | Irm Llc | compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos |
| WO2008073687A2 (en) * | 2006-12-08 | 2008-06-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EA019094B1 (ru) * | 2008-08-22 | 2014-01-30 | Новартис Аг | Пирролопиримидины и их применение |
| EP2429566B1 (en) * | 2009-05-13 | 2016-01-06 | The University of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| KR101830455B1 (ko) * | 2010-04-13 | 2018-02-20 | 노파르티스 아게 | 시클린 의존성 키나제 ４ 또는 시클린 의존성 키나제 （ｃｄｋ４／６） 억제제 및 ｍｔｏｒ 억제제를 포함하는 암 치료를 위한 조합물 |
| HUE025395T2 (en) * | 2011-02-02 | 2016-02-29 | Novartis Ag | Methods using ALK inhibitors |
-
2014
- 2014-08-28 ES ES14766301.7T patent/ES2674361T3/es active Active
- 2014-08-28 RU RU2016110874A patent/RU2016110874A/ru not_active Application Discontinuation
- 2014-08-28 CN CN201480059490.0A patent/CN106029099A/zh active Pending
- 2014-08-28 CA CA2922684A patent/CA2922684A1/en not_active Abandoned
- 2014-08-28 US US14/913,828 patent/US20160361314A1/en not_active Abandoned
- 2014-08-28 JP JP2016537859A patent/JP6479812B2/ja not_active Expired - Fee Related
- 2014-08-28 EP EP14766301.7A patent/EP3038652B1/en active Active
- 2014-08-28 MX MX2016002580A patent/MX2016002580A/es unknown
- 2014-08-28 BR BR112016004358A patent/BR112016004358A8/pt not_active IP Right Cessation
- 2014-08-28 AU AU2014312261A patent/AU2014312261A1/en not_active Abandoned
- 2014-08-28 KR KR1020167007656A patent/KR20160047521A/ko not_active Withdrawn
- 2014-08-28 WO PCT/US2014/053244 patent/WO2015031666A1/en not_active Ceased
-
2017
- 2017-08-25 AU AU2017219093A patent/AU2017219093A1/en not_active Abandoned
-
2018
- 2018-07-16 US US16/035,774 patent/US20180318305A1/en not_active Abandoned
- 2018-09-27 AU AU2018236813A patent/AU2018236813A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3038652A1 (en) | 2016-07-06 |
| CN106029099A (zh) | 2016-10-12 |
| AU2018236813A1 (en) | 2018-10-18 |
| BR112016004358A8 (pt) | 2020-02-11 |
| JP6479812B2 (ja) | 2019-03-06 |
| ES2674361T3 (es) | 2018-06-29 |
| US20160361314A1 (en) | 2016-12-15 |
| RU2016110874A (ru) | 2017-10-04 |
| JP2016529285A (ja) | 2016-09-23 |
| AU2017219093A1 (en) | 2017-09-14 |
| CA2922684A1 (en) | 2015-03-05 |
| EP3038652B1 (en) | 2018-03-21 |
| KR20160047521A (ko) | 2016-05-02 |
| WO2015031666A1 (en) | 2015-03-05 |
| MX2016002580A (es) | 2016-10-26 |
| AU2014312261A1 (en) | 2016-03-10 |
| US20180318305A1 (en) | 2018-11-08 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20200415 |